Medicamen Biotech Share Price History and Returns 2006 to 2026
|
Medicamen Biotech Limited |
|||
|
Price: ₹223.50 (-9.02%) | ||
| 52 Week Low: ₹216.95 52 Week High: ₹447.65 |
|||
| Market Capital: 349.45 Crore (Small-cap) | |||
| Healthcare -> Drug Manufacturers - Specialty & Generic | |||
Share Price HistoryMEDICAMEQ FinancialsTomorrow TargetYearly TargetsDividend HistoryNo BonusNo Split
Show Table of Contents
Table of Contents
- 1: Medicamen Biotech Stock Highlights
- 1.1: 52-Week High Low
- 1.2: All Time High
- 2: Medicamen Biotech Recent Performance
- 3: Medicamen Biotech Stock Price Chart From 2021 to 2026
- 4: Medicamen Biotech Stock Price History Table From 2021 to 2026
- 5: Analyzing the Impact of Investing in Medicamen Biotech
- 5.1: Medicamen Biotech Stock Returns In Last 5 Years
- 6: Medicamen Biotech Returns vs Bank FD Returns
Medicamen Biotech Stock Highlights
As of 08 Jun 2026, Medicamen Biotech Stock price is ₹223.50 which is ₹224.15 below 52-week high of ₹447.65 and ₹6.55 above 52-week low of ₹216.95
52-Week High Low
- Medicamen Biotech 52-Week High is ₹447.65 occurred on 25 Nov 2025
- Medicamen Biotech 52-Week Low is ₹216.95 occurred on 30 Mar 2026
All Time High
- The all-time high or the highest price that Medicamen Biotech stocks have ever touched was ₹1,225.00 and this occurred on Sep 2022.
- The highest closing price at which Medicamen Biotech stocks have ever closed was ₹1,177.05 recorded on Aug 2022.
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Medicamen Biotech Recent Performance
Over the past 15 trading days, the value of Medicamen Biotech's stock has decreased by ₹45.70 (-16.98%). On 19 May 2026, its one share was worth ₹269.2 and by 08 Jun 2026, the value dropped to ₹223.5. During this period it created a highest high of ₹300.80 and lowest low of ₹218.00.
Click on legend items to show/hide respective price lines
Medicamen Biotech Stock Price Chart From 2021 to 2026
Click on legend items to show/hide respective price lines
Medicamen Biotech Stock Price History Table From 2021 to 2026
| Year | Medicamen Biotech | YOY Chg% | ↑High - ↓Low |
|---|---|---|---|
| 2026 | ₹245.65 | -32.7% |
↑ ₹406.00 ↓ ₹216.00 |
| 2025 | ₹364.65 | -28.9% |
↑ ₹560.00 ↓ ₹292.00 |
| 2024 | ₹512.45 | -15.1% |
↑ ₹630.00 ↓ ₹355.00 |
| 2023 | ₹603.15 | -27.4% |
↑ ₹888.00 ↓ ₹552.00 |
| 2022 | ₹830.50 | -6.5% |
↑ ₹1,225.00 ↓ ₹557.00 |
| 2021 | ₹887.60 | - |
↑ ₹1,019.00 ↓ ₹539.00 |
Analyzing the Impact of Investing in Medicamen Biotech
Medicamen Biotech Stock price in the year 2021 was ₹887.60. If you had invested ₹10,000 in Medicamen Biotech Stock in 2021, in 5 years, your investment would have reduced to ₹2,767 by the end of 2026. This represents a negative return of -72.4% from 2021 to 2026, with a compound annual growth rate (CAGR) of -22.7%.
Medicamen Biotech Stock Returns In Last 5 Years
- Its highest stock price in the last 5 years was: ₹1,225.00 and lowest was: ₹216.95
- Medicamen Biotech Stock price in 2021 was ₹887.60
- By 2026, its stock price dropped to ₹245.65
- It gave a negative return of over -72.3% with a CAGR of -22.7% over the last 5 years
- If you had invested ₹10,000 in Medicamen Biotech in 2021 then in 5 years, your investment would have declined to ₹2,767.57 by 2026.
Medicamen Biotech Returns vs Bank FD Returns
| Investment Type | Initial Amount | Final Value | Total Returns |
|---|---|---|---|
| Medicamen Biotech Shares | ₹10,000 | ₹2,767.57 | -72.3% |
| Bank FD (Simple Interest) | ₹10,000 | ₹13,000 | 30.0% |
| Bank FD (Compound Interest) | ₹10,000 | ₹13,382.25 | 33.8% |
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
